279 related articles for article (PubMed ID: 12654190)
41. [Experiment study on the diagnostic value of bile K-ras gene mutation responsible to the hepatic metastasis of pancreatic cancer].
Zhou X; Zhang ZD; Tian BL; Han FH; Hu WM; Jia W; Lu HM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar; 38(2):309-11, 327. PubMed ID: 17441357
[TBL] [Abstract][Full Text] [Related]
42. Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing.
Wei S; Liang Z; Gao J; Wu S; Zhu H; Liu H; Liu T
J Gastroenterol Hepatol; 2005 Jan; 20(1):67-72. PubMed ID: 15610449
[TBL] [Abstract][Full Text] [Related]
43. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
44. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations.
Uehara H; Nakaizumi A; Tatsuta M; Baba M; Takenaka A; Uedo N; Sakai N; Yano H; Iishi H; Ohigashi H; Ishikawa O; Okada S; Kakizoe T
Am J Gastroenterol; 1999 Sep; 94(9):2513-8. PubMed ID: 10484017
[TBL] [Abstract][Full Text] [Related]
45. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
46. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
47. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts.
Sreenarasimhaiah J; Lara LF; Jazrawi SF; Barnett CC; Tang SJ
JOP; 2009 Mar; 10(2):163-8. PubMed ID: 19287110
[TBL] [Abstract][Full Text] [Related]
48. CA19-9: the Italian experience.
Gullo L
Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
[TBL] [Abstract][Full Text] [Related]
49. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
Mueller J; Gansauge S; Mattfeldt T
Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
[TBL] [Abstract][Full Text] [Related]
50. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma.
Dillon DA; Johnson CC; Topazian MD; Tallini G; Rimm DL; Costa JC
Cancer J; 2000; 6(5):294-301. PubMed ID: 11079168
[TBL] [Abstract][Full Text] [Related]
51. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract][Full Text] [Related]
52. Assay design and optimization of mutant-enriched PCR based method for detection of K-ras gene mutations in pancreatic carcinoma.
Ugorcáková J; Hlavatý T; Babál P; Janega P; Bukovská G; Halgasová N; Hlavatá A; Timko J; Duris I
Neoplasma; 2006; 53(5):363-71. PubMed ID: 17013530
[TBL] [Abstract][Full Text] [Related]
53. The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues.
Kraus MC; Seelig MH; Linnemann U; Berger MR
Int J Oncol; 2006 Oct; 29(4):957-64. PubMed ID: 16964391
[TBL] [Abstract][Full Text] [Related]
54. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
55. Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC).
Chien CC; Chen SH; Liu CC; Lee CL; Yang RN; Yang SH; Huang CJ
Transl Res; 2007 Feb; 149(2):96-102. PubMed ID: 17240321
[TBL] [Abstract][Full Text] [Related]
56. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
[TBL] [Abstract][Full Text] [Related]
57. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
58. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma.
Watanabe H; Ha A; Hu YX; Ohtsubo K; Yamaguchi Y; Motoo Y; Okai T; Toya D; Tanaka N; Sawabu N
Cancer; 1999 Oct; 86(8):1441-8. PubMed ID: 10526271
[TBL] [Abstract][Full Text] [Related]
59. [Characteristics of plasma DNA and its application for detection of K-ras gene mutation].
Hayashi T; Sugahara K; Dateki N; Yamada Y; Sudou R; Kanematsu T; Kamihira S
Rinsho Byori; 2000 Jun; 48(6):547-53. PubMed ID: 10897674
[TBL] [Abstract][Full Text] [Related]
60. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]